FGFR1 and IGFR1 participate in a signaling network that includes EGFR and other ERBB family members (Fig. 1c), and both can contribute to resistance to EGFR-targeted therapeutics, the only type of targeted therapy approved for HNSCC [73, 95, 96]. Here, EGFR is linked to head and neck squamous cell carcinoma.